Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – ...

US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has said he will cut $500 million in funding for mRNA ...

Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...

The market report provides current cardiotoxicity treatment practices, emerging drugs, market share of individual therapies, ...

Welcome to Contract Pharma’s annual ranking of the Top 20 Pharma and Biopharma Companies, based on fiscal year 2024 ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Soligenix's HyBryte (synthetic hypericin) offers a promising solution as a potential first-line therapy for early-stage CTCL. By addressing this critical gap in care, HyBryte has the potential to ...

As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that ...

Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antib ...

A major milestone for OPKO Health was the FDA’s approval of a supplemental application for the 4Kscore test. This approval allows the test to be performed without digital rectal examination ...

Once a market darling during the early pandemic years, Pfizer (NYSE: PFE) has been on a straight southbound path for several ...